St. Jude Medical Halts Enlightn IV Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

St. Jude Medical (NYSE:STJ) is calling off the Enlightn IV trial of the next generation of its renal denervation technology, just a few months after it began.

The trial of St. Jude's multi-electrode Enlightn device was slated to enroll about 590 patients between the ages of 18 and 80 with high blood pressure that isn't well-managed with drugs.

Help employers find you! Check out all the jobs and post your resume.

Back to news